AARTIPHARM - Aarti Pharma

📊 NSE: AARTIPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 17:44

💰 Financial Performance

Revenue Growth by Segment

Consolidated operational revenue for Q2 FY26 was INR 418.3 Cr, representing an 8.7% YoY decline from INR 458 Cr. Segmentally, Xanthine Derivatives performed better than the previous year, and CDMO-CMO sales were higher YoY. However, overall API sales were significantly lower than the previous year, contributing to the top-line contraction.

Geographic Revenue Split

Not specifically disclosed in available documents, though the company maintains a strong presence in international markets and established relationships with global clients.

Profitability Margins

Gross and EBITDA margins saw a sharp decline in Q2 FY26. Consolidated PAT for Q2 FY26 was INR 27.9 Cr, a 48.9% decrease from INR 54.6 Cr in Q2 FY25. PAT margin contracted by 525 bps to 6.67% from 11.92% YoY. Profitability was impacted by a Forex loss of INR 7.4 Cr and the accounting of WIP for large orders where invoicing only occurs upon final delivery.

EBITDA Margin

Consolidated EBITDA for Q2 FY26 stood at INR 74.7 Cr, down 20.3% YoY from INR 93.7 Cr. The EBITDA margin was 17.86%, a contraction of 260 bps from 20.46% in Q2 FY25. This was driven by higher operating expenses (INR 343.6 Cr) and a shift in manufacturing focus toward early-stage intermediates which occupy capacity without immediate profit recognition.

Capital Expenditure

The company is executing a total planned investment of INR 550 Cr. This includes a Greenfield project at Atali, Gujarat (INR 400 Cr) for Intermediates and CDMO/CMO with a 450 KL capacity, and a Brownfield expansion at Tarapur, Maharashtra (INR 150 Cr) to add 9,000 MTPA capacity for Xanthine Derivatives. Both are expected to ramp up/commission by Q4 FY26.

Credit Rating & Borrowing

CRISIL has assigned a 'Stable' outlook. The company maintains a strong financial risk profile with a gearing ratio of 0.14 and total outside liabilities to adjusted networth of 0.44 as of March 31, 2023. Interest coverage was healthy at 16.36 times for fiscal 2023.

⚙️ Operational Drivers

Raw Materials

Key raw materials include intermediates for APIs and Xanthine derivatives. Specific chemical names are not listed, but raw materials constitute a significant portion of the INR 343.6 Cr operating expenses in Q2 FY26.

Import Sources

More than 33% of raw materials are imported from international markets, making the company susceptible to global supply chain disruptions and currency fluctuations.

Key Suppliers

Not disclosed in available documents; however, the company maintains healthy relations with a diverse base of global suppliers.

Capacity Expansion

Current Xanthine Derivative capacity at Tarapur is 9,000 MTPA with nearly 100% utilization. Expansion will add another 9,000 MTPA by Q4 FY26. The Atali Greenfield site (Phase 1: 450 KL) is scalable up to 8-10x its initial capacity to support long-term CDMO growth.

Raw Material Costs

Operating expenses, primarily driven by raw materials, were INR 343.6 Cr in Q2 FY26. While expenses decreased 5.7% YoY, they rose 18.1% QoQ, impacting margins. The company has a limited ability to pass on sharp increases in input prices to customers.

Manufacturing Efficiency

Current Xanthine capacity utilization is at 100%. Efficiency is being optimized by transferring more intermediates to current sites to fill capacity while new blocks are qualified through audits.

📈 Strategic Growth

Expected Growth Rate

8-12%

Growth Strategy

Growth will be driven by the commissioning of the Atali Greenfield site (INR 400 Cr) which targets the high-growth CDMO/CMO segment and the Tarapur Brownfield expansion (INR 150 Cr) to capture a larger wallet share of the beverage market. The company is also focusing on deep backward integration (8-10 stages in-house) to improve value capture.

Products & Services

Xanthine Derivatives (Caffeine, Theophylline) sold to the beverage industry, Active Pharmaceutical Ingredients (APIs), and Intermediates, alongside CDMO-CMO services for global pharma players.

Brand Portfolio

Aarti Pharmalabs (formerly Aarti Organics Ltd).

New Products/Services

New product development is focused on the CDMO/CMO segment and expanded Xanthine derivatives, with the Atali site designed specifically as a growth engine for these new lines.

Market Expansion

Expansion is targeted at the beverage customer segment and the global CDMO market, utilizing the 80-acre Atali land bank which allows for 8-10x Phase 1 scaling.

Strategic Alliances

Ganesh Polychem Limited became a Joint Venture effective April 1, 2025, following an addendum to the Shareholding Agreement.

🌍 External Factors

Industry Trends

The industry is shifting toward integrated CDMO models. Aarti Pharmalabs is positioning itself by expanding intermediate capacity and offering 8-10 stage in-house manufacturing to provide certainty to global customers.

Competitive Landscape

Faces intense competition in the API and Intermediate business, which contributed to lower API sales in the most recent quarter.

Competitive Moat

The moat is built on deep backward integration, established long-term relationships with beverage giants, and a strong financial profile (0.14 gearing). These are sustainable due to the high capital intensity and regulatory hurdles of the API/Xanthine industry.

Macro Economic Sensitivity

Highly sensitive to global pharmaceutical demand and raw material pricing cycles. A decline in operating margins below 18% is flagged as a rating sensitivity factor.

Consumer Behavior

Growth in the beverage segment is a key driver for Xanthine derivatives, leading to the 100% utilization of current capacity.

Geopolitical Risks

Exposure to international trade regulations and supply chain risks from the 33% import dependency.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to stringent pharmaceutical manufacturing standards and audits; the company recently underwent audits to qualify facilities for future manufacturing blocks.

Taxation Policy Impact

The effective tax expense for Q2 FY26 was INR 10.8 Cr, representing approximately 27.9% of PBT.

⚠️ Risk Analysis

Key Uncertainties

Key risks include the successful ramp-up of the INR 550 Cr capex projects by Q4 FY26 and the volatility of raw material prices which could keep margins below the 18% threshold.